Personal Injury Law

Hard To Treat Diseases (HTDS) Offers Hepatitis A Vaccine in India

By Marler Clark LLP

This release from a single company speaks volumes about the size of the Hepatitis A vaccine market in India, which has developed in only the last few years.  It says:

 Hard To Treat Diseases (HTDS)  says its China based operating subsidiary Mellow Hope has surpassed sales of 200,000 units of Hepatitis A Vaccine in India.

The Hepatitis A Vaccine (BIOVAC-A) was first launched in the market of India in December, 2005.

Terry Yuan, CEO added "Because our product is single-dose vaccine, so (sic) our price is almost the half of other multinational competitors' price. Our sales volume keeps growing continuously. To well promote our AV and convince the local people that our product is equal or better to our multinational competitors, we had conducted a Multi-centric clinical trial in 2007. The results proved that our product offers great safety and efficacy. Subsequently, this trial report was published in the International Journal. As a company, we hold two seminars' every year, one in India and one in China".

The company will provide further details as they become available. 

Full post as published by Hepatitis Blog on April 14, 2009 (boomark / email).